Mesoblast Ltd (MSB) - Total Assets

Latest as of December 2025: AU$782.31 Million AUD ≈ $553.53 Million USD

Based on the latest financial reports, Mesoblast Ltd (MSB) holds total assets worth AU$782.31 Million AUD (≈ $553.53 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Mesoblast Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Mesoblast Ltd - Total Assets Trend (2005–2025)

This chart illustrates how Mesoblast Ltd's total assets have evolved over time, based on quarterly financial data. Explore Mesoblast Ltd (MSB) long-term investment share to see how much of total assets are deployed in long-term investments.

Mesoblast Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

Mesoblast Ltd's total assets of AU$782.31 Million consist of 26.0% current assets and 74.0% non-current assets.

Asset Category	Amount (AUD)	% of Total Assets
Cash & Equivalents	AU$0.00	20.5%
Accounts Receivable	AU$14.87 Million	1.9%
Inventory	AU$22.25 Million	2.8%
Property, Plant & Equipment	AU$5.82 Million	0.7%
Intangible Assets	AU$437.37 Million	55.7%
Goodwill	AU$134.45 Million	17.1%

Asset Composition Trend (2005–2025)

This chart illustrates how Mesoblast Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mesoblast Ltd stock valuation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Mesoblast Ltd's current assets represent 26.0% of total assets in 2025, a decrease from 71.4% in 2005.
Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, down from 70.3% in 2005.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 3.0% in 2005.
Asset Diversification: The largest asset category is intangible assets at 55.7% of total assets.

Mesoblast Ltd Competitors by Total Assets

Key competitors of Mesoblast Ltd based on total assets are shown below.

Company	Country	Total Assets
CSL Ltd AU:CSL	Australia	AU$39.54 Billion
BB Biotech AG SW:BION	Switzerland	CHF2.64 Billion
Concord Biotech Limited NSE:CONCORDBIO	India	Rs20.23 Billion
Pharming Group NV AS:PHARM	Netherlands	€473.79 Million
Innovita Biological Technology Co. Ltd. A SHG:688253	China	CN¥2.23 Billion
Wuhan Keqian Biology Co Ltd SHG:688526	China	CN¥4.75 Billion
Clarity Pharmaceuticals Ltd AU:CU6	Australia	AU$255.67 Million
OPTHEA LTD (SP.ADR/8) F:UKJ2	Germany	€145.77 Million

Mesoblast Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.58	0.96	0.99
Quick Ratio	1.41	0.63	0.99
Cash Ratio	0.00	0.00	0.00
Working Capital	AU$74.41 Million	AU$-3.07 Million	AU$-582.00K

Mesoblast Ltd - Advanced Valuation Insights

This section examines the relationship between Mesoblast Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.23
Latest Market Cap to Assets Ratio	2.48
Asset Growth Rate (YoY)	17.3%
Total Assets	AU$784.68 Million
Market Capitalization	$1.95 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values Mesoblast Ltd's assets at a significant premium (2.48x), suggesting investors see substantial growth potential or unique competitive advantages.

Rapid Asset Growth: Mesoblast Ltd's assets grew by 17.3% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Mesoblast Ltd (2005–2025)

The table below shows the annual total assets of Mesoblast Ltd from 2005 to 2025.

Year	Total Assets	Change
2025-06-30	AU$784.68 Million ≈ $555.21 Million	+17.27%
2024-06-30	AU$669.15 Million ≈ $473.47 Million	-0.04%
2023-06-30	AU$669.41 Million ≈ $473.65 Million	+1.10%
2022-06-30	AU$662.14 Million ≈ $468.51 Million	-11.09%
2021-06-30	AU$744.72 Million ≈ $526.93 Million	+1.52%
2020-06-30	AU$733.60 Million ≈ $519.07 Million	+12.50%
2019-06-30	AU$652.12 Million ≈ $461.41 Million	-5.82%
2018-06-30	AU$692.44 Million ≈ $489.95 Million	+5.61%
2017-06-30	AU$655.69 Million ≈ $463.94 Million	-4.14%
2016-06-30	AU$684.02 Million ≈ $483.99 Million	-32.80%
2015-06-30	AU$1.02 Billion ≈ $720.25 Million	+13.19%
2014-06-30	AU$899.31 Million ≈ $636.32 Million	+1.77%
2013-06-30	AU$883.71 Million ≈ $625.28 Million	+22.66%
2012-06-30	AU$720.46 Million ≈ $509.77 Million	-5.61%
2011-06-30	AU$763.25 Million ≈ $540.05 Million	+1831.56%
2010-06-30	AU$39.51 Million ≈ $27.96 Million	+46.49%
2009-06-30	AU$26.98 Million ≈ $19.09 Million	-2.93%
2008-06-30	AU$27.79 Million ≈ $19.66 Million	+30.84%
2007-06-30	AU$21.24 Million ≈ $15.03 Million	+29.62%
2006-06-30	AU$16.38 Million ≈ $11.59 Million	-23.67%
2005-06-30	AU$21.47 Million ≈ $15.19 Million	--

About Mesoblast Ltd

AU:MSB Australia Biotechnology

Market Cap

$1.95 Billion

AU$2.75 Billion AUD

Market Cap Rank

#6400 Global

#148 in Australia

Share Price

AU$2.13

Change (1 day)

+3.40%

52-Week Range

AU$1.57 - AU$3.07

All Time High

AU$5.21